A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
Price : $35 *
At a glance
- Drugs IMAB 027 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; First in man
- Acronyms OVAR
- Sponsors Ganymed Pharmaceuticals
- 30 Jun 2017 Status changed from active, no longer recruiting to completed.
- 16 Mar 2017 Time frame of primary endpoint has changed from 5 months to 24 months.
- 16 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.